Free Trial

Gerresheimer (ETR:GXI) Stock Price Down 0.5% - What's Next?

Gerresheimer logo with Medical background

Gerresheimer AG (ETR:GXI - Get Free Report) fell 0.5% during trading on Friday . The company traded as low as €45.04 ($51.77) and last traded at €45.54 ($52.34). 123,598 shares were traded during mid-day trading, a decline of 12% from the average session volume of 140,925 shares. The stock had previously closed at €45.76 ($52.60).

Gerresheimer Stock Performance

The company has a current ratio of 0.80, a quick ratio of 0.40 and a debt-to-equity ratio of 87.94. The stock's 50 day moving average is €55.04 and its 200 day moving average is €66.28. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of 13.64, a PEG ratio of 0.82 and a beta of 0.94.

Gerresheimer Company Profile

(Get Free Report)

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gerresheimer Right Now?

Before you consider Gerresheimer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gerresheimer wasn't on the list.

While Gerresheimer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Bought This Stock at the Bottom—Will You Miss It?
The Drone Industry Is About to 10X—Here’s How to Profit
Why AMD Stock Beats NVIDIA Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines